Advertisement

Topics

Ixekizumab (Taltz) - Biotech, Pharma and Life Science Channel

21:02 EST 7th December 2016 | BioPortfolio

Ixekizumab (Taltz) is a humanised IgG4 monoclonal antibody that selectively binds with high affinity to the interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.iii IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses, and elevated levels of IL-17A have been implicated in the pathogenesis of a variety of autoimmune diseases such as psoriasis.iii  Neutralisation of IL-17A by ixekizumab inhibits these pro-inflammatory actions.iii

Ixekizumab is administered by subcutaneous injection, either via auto-injector or prefilled syringe.iii

In UNCOVER-1 the results show that when treated every two weeks with ixekizumab for 12 weeks following a starting dose, approximately 9 of 10 patients achieved a PASI 75 score.iiiIn both UNCOVER-2 and UNCOVER-3 etanercept was used as an active comparator. The results show that approximately 9 of 10 patients treated with ixekizumab every two weeks achieved a PASI 75 score at week 12, and approximately 8 of 10 patients achieved clear or almost clear skin as defined by sPGA 0 or 1 respectively.iii,

Numerous secondary end points were also collected from the UNCOVER series of trials, including higher levels of clearance, (PASI 90, 100 and sPGA 0). The impact of psoriasis on patient's lives was assessed using patient reported outcome measures, including the DLQI. Across UNCOVER-1 and UNCOVER 2&3, 35.3 percent and 39 percent of patients, respectively achieved PASI 100 (clear skin) after 12 weeks of treatment with ixekizumab.iii

The approved dosing regimen for ixekizumab is a 160-mg starting dose by subcutaneous injection (two 80-mg injections) at Week 0, followed by 80 mg (one injection) every two weeks through 12 weeks, then maintenance dosing of 80 mg (one injection) every four weeks.iii

Lilly received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on February 25, 2016.v

Safety information

The very common (≥1/10 patients) adverse events in clinical trials were injection site reactions and upper respiratory tract infections (most frequently nasopharyngitis).iii

About the UNCOVER Studies

The UNCOVER-1, UNCOVER-2 and UNCOVER-3 studies are double-blind, multicentre, Phase III studies evaluating more than 3,800 patients with moderate-to-severe plaque psoriasis from 21 countries.iii

All three studies evaluated the safety and efficacy of different dosing regimens of ixekizumab (80 mg every two or four weeks, following a 160-mg starting dose) compared to placebo after 12 weeks.iii

·       UNCOVER-2 and UNCOVER-3 included an additional comparator arm in which patients received etanercept (50 mg twice a week) for 12 weeks.iv

·       UNCOVER-1, UNCOVER-2 and UNCOVER-3 also evaluated response rates with ixekizumab during the maintenance period through 60 weeks, with UNCOVER-1 and UNCOVER-2 employing a randomized withdrawal design.iii,iv

·       In these studies, the co-primary efficacy endpoints at 12 weeks were Psoriasis Area Severity Index (PASI) 75 and static Physician’s Global Assessment (sPGA) 0 or 1.iiiPASI measures the extent and severity of psoriasis by assessing average redness, thickness and scaliness of skin lesions (each graded on a zero to four scale), weighted by the body surface area of involved skin, while the sPGA is the physician’s assessment of severity of a patient’s psoriasis lesions overall at a specific point in time.vi Both assessment tools (PASI and sPGA) are in line with CHMP guidelines to assess the effectiveness of treatments for psoriasis.vii

 

News Articles [103 Associated News Articles listed on BioPortfolio]

Global Systemic Psoriasis Therapeutics Market 20162020 Prices from USD $2500

About the Systemic Psoriasis Therapeutics Market Psoriasis is a commonly diagnosed immunemediated disease of the skin. In psoriasis, the skin grows fast and causes a buildup of red, thick white, or s...

Lycera Announces Initiation of Phase 2 UPRISE Clinical Trial of LYC-30937-EC for Patients with Moderate Psoriasis

NEW YORK and ANN ARBOR, Mich., Dec. 7, 2016 /PRNewswire/ -- Lycera Corp., a privately held biopharmaceutical company developing breakthrough immune modulatory medicines, announced today the initi...

New Report Finds All Reviewed Psoriasis Therapies a Good Value Calls for Abolishing or Limiting Step Therapy

PORTLAND, Ore., Dec. 6, 2016  The National Psoriasis Foundation (NPF), a non-profit organization whose mission is to drive efforts to cure psoriatic disease and improve the lives of those affecte...

Sienna Biopharmaceuticals Acquires Creabilis plc

WESTLAKE VILLAGE, Calif., Dec. 6, 2016 /PRNewswire/ -- Sienna Biopharmaceuticals, Inc., a privately held, clinical-stage medical dermatology and aesthetics company, today announced it has acquire...

Psoriasis Japan Drug Forecast and Market Analysis to 2024 Prices from USD $4995

Psoriasis Japan Drug Forecast and Market Analysis to 2024SummaryPsoriasis PsO is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 23% worldwide. S...

New Guidelines Empower Psoriasis Patients to Reach Significant Treatment Goals

PORTLAND, Ore., Dec. 1, 2016 /PRNewswire-USNewswire/ -- More than 8 million people in the U.S. have psoriasis and current methods of managing the disease have resulted in patient frustration, largely ...

AbbVie Receives Orphan Drug Designation for Investigational IL-23 Inhibitor Risankizumab from the U.S. Food and Drug Administration for the Treatment of Pediatric Patients with Crohn's Disease

 - Orphan Drug Designation program provides orphan status to medications intended for the safe and effective treatment, diagnosis or prevention of rare diseases[1] - Risankizumab is an inves...

Autoimmune Diseases Market in the US 20152019 Prices from USD $2500

About Autoimmune DiseasesAutoimmune diseases are caused by aggravation of the immune system. Autoimmune diseases can last for months or even years. Autoimmune reactions occur when the immune system pr...

Psoriasis India Drug Forecast and Market Analysis to 2024 Prices from USD $4995

Psoriasis India Drug Forecast and Market Analysis to 2024SummaryPsoriasis PsO is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 23% worldwide. S...

Psoriasis US Drug Forecast and Market Analysis to 2024 Prices from USD $4995

Psoriasis US Drug Forecast and Market Analysis to 2024SummaryPsoriasis PsO is an incurable genetic, systemic, inflammatory, and chronic skin disorder with an overall prevalence of 23% worldwide. Spec...

Events [0 Results]

None

Companies [19 Associated Companies listed on BioPortfolio]

Santalis Pharmaceuticals, Inc.

Santalis Pharmaceuticals, Inc. is a wholly-owned subsidiary of TFS Corporation, Ltd. (ASX: TFC). Santalis, and its sister company, ViroXis, were acquired by TFS in July 2015 and a...

Ziarco Pharma Ltd.

Ziarco is a clinical-stage biotechnology company developing innovative therapeutics targeting dermatological and inflammatory diseases. ZPL-389, the Company’s lead compound, ...

Akaal Pharma Pty Ltd.

Akaal Pharma Pty Ltd (Akaal Pharma) is a clinical-stage drug discovery and development company focused on the development of novel small molecule drugs for the treatment of inflam...

Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells...

Shape Pharmaceuticals, Inc.

Shape Pharmaceuticals, Inc. is developing SHP-141, a novel, topical, “soft-drug” HDAC inhibitor for the treatment of patients with cutaneous T cell lymphoma (CTCL) and p...

Helmedix Pty Ltd

Helmedix is developing new therapies for autoimmune diseases. The company has identified peptides derived from helminthic worms that have immune-modulating properties. These peptides are being explo...

HealOr

Founded in 2002, HealOr is a privately owned, clinical-stage specialty biopharmaceutical company developing a first-in-class pipeline of topical therapeutics to treat a variety of...

fOCUS Pharmaceuticals, LLC

fOCUS Pharmaceuticals is a privately held generic and branded pharmaceutical company specializing in the research and development of prescription dermatology products. Our primary focus are in the are...

Lycera Corp.

Lycera Corp. is focused on the discovery and development of small-molecule immunomodulators for the treatment of immunologic diseases, including psoriasis, rheumatoid arthritis, lupus erythematosis, i...

Galderma Laboratories, L.P.

Galderma, created in 1981 as a joint venture between Nestle and L'Oreal, is a fully-integrated specialty pharmaceutical company dedicated exclusively to the field of dermatology. The Company has a pre...

Clinical Trials [491 Associated Clinical Trials listed on BioPortfolio]

Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray

A single center, study of 20 subjects to assess 4 weeks of therapy with Topicort® twice daily BID and 12 weeks twice daily on 2 consecutive days to patients with scalp psoriasis

Topical Psoriasis Study for Patients Receiving Biologic Therapy

A two-phase, single center, study of 20 subjects to assess 4 weeks of add-on therapy of Topicort® BID and 12 weeks BID on two consecutive days a week to patients with ≤5% BSA who are re...

A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea

The primary objective of this study is to evaluate the efficacy and safety of KHK4827 in subjects with moderate to severe plaque psoriasis randomized in a double-blind manner to receive KH...

BI655130 Single Dose in Generalized Pustular Psoriasis

This is a phase I, open label, single group study that is being performed to assess the safety, tolerability, Pharmacokinetics (PK) , Pharmacogenomics (PGx) and efficacy of a single dose o...

Insulin Sensitivity, Glucose - and Fat Metabolism in Patients With Psoriasis

The pathophysiological mechanisms explaining the association between psoriasis and type 2 diabetes are largely unknown but it has been hypothesized that systemic inflammation found in both...

A Phase I, Double Blind, Randomized, Placebo Controlled, Maximal Dose Study to Determine the Safety, Tolerability of Topical Cream Containing MGC (Medical Grade Cannabis) in Healthy Volunteers

This single center, prospective, double-blind, placebo-controlled, randomized two parts study (part I and part II) will assess the safety of topical cream (3% CBD and 3% THC), applied twic...

Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD0284 in Healthy Subjects

Plaque psoriasis vulgaris is a chronic inflammatory skin disorder, affecting 1-3% of the population in Europe and the United States of America (USA) and represents one of the most prevalen...

Vasoconstriction Trial With LEO 90100 Aerosol Foam

Vasoconstriction study with LEO 90100

A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pefcalcitol Ointment, 0.005%, Applied Topically Twice Daily (BID) for 8 Weeks in Adolescent Subjects 12 to < 17 Years of Age With Plaque

A multi-center, open-label study that will evaluate the safety/tolerability and pharmacodynamics as well as the pharmacokinetic profile (sub-population analysis), in 50 evaluable adolescen...

Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis

The purpose of this study is to determine whether PF-06700841 is safe and effective in the treatment of chronic plaque psoriasis.

PubMed Articles [291 Associated PubMed Articles listed on BioPortfolio]

Biological therapies (immunomodulatory drugs), worsening of psoriasis and rebound effect: new evidence of similitude.

Employing the secondary action or adaptative reaction of the organism as therapeutic response, homeopathy uses the treatment by similitude (similia similibus curentur) administering to sick individual...

c-CBL E3 Ubiquitin Ligase Expression Increases Across the Spectrum of Benign and Malignant T-Cell Skin Diseases.

Prolonged survival of lesional T cells plays a central role in the pathogenesis of T-cell-mediated dermatoses. We have recently shown that the ubiquitin ligase c-CBL is highly expressed in cutaneous T...

Assessment of Interleukin 16 Serum Levels and Skin Expression in Psoriasis Patients in Correlation with Clinical Severity of the Disease.

Interleukin 16 (IL-16) has been described as a significant cytokine involved in the recruitment of CD4+ cells during inflammation; however, its potential role in psoriasis has not been defined. Our ai...

The EGALITY study: A confirmatory, randomised, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, versus the originator product in patients with moderate to severe chronic plaque-type psoriasis.

GP2015 is a proposed etanercept biosimilar.

Increased global arterial and subcutaneous adipose tissue inflammation in patients with moderate-to-severe psoriasis.

Psoriasis is associated with cardiovascular disease and it has been proposed that the increased cardiovascular risk is caused by low-grade systemic inflammation involving organs and tissues other than...

The emergence of the IL-36 cytokine family as novel targets for inflammatory diseases.

The recently discovered interleukin (IL)-36 family of cytokines form part of the broader IL-1 family and are emerging as important mediators of inflammatory disease. The IL-36 subfamily consists of th...

Healthcare Resource Utilization, Healthcare Costs, and Dose Escalation in Psoriasis Patients Initiated on Ustekinumab versus Adalimumab: A Retrospective Claim Study.

Adalimumab and ustekinumab are effective psoriasis treatments. This study compares healthcare resource utilization (HRU), costs and dose escalation, and describes starting dose trends in ustekinumab v...

Roles of MicroRNAs in Psoriasis: Immunological Functions and Potential Biomarkers.

MicroRNAs (miRNAs) are small non-coding RNA molecules, which function in RNA silencing and post-transcriptional regulation of gene expression. Psoriasis is an inflammatory skin disease characterized b...

Psoriasiform Eruption and Worsening of Pustulosis Palmoplantaris After Treatment with Two Anti-TNF-α Inhibitors, Followed by Successful Treatment with Ustekinumab.

Tumor necrosis factor (TNF)-α inhibitors are widely used for the treatment of inflammatory diseases. One of the side effects of TNF-inhibitors is the development of a psoriatiform eruption, also know...

Evaluation of potent phytomedicine for treatment of psoriasis using UV radiation induced psoriasis in rats.

The aim of present study was to determine the effect of newly formulated gels and suspensions of extractive Phytoconstituents of Woodfordia fructicosa flowers and Gardenia gummifera leaves by using UV...

Videos

None available.

Medical and Biotech [MESH] Definitions

A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.

A topical anti-inflammatory glucocorticoid used in DERMATOSES, skin allergies, PSORIASIS, etc.

A glucocorticoid used topically in the treatment of DERMATITIS; ECZEMA; or PSORIASIS. It may cause skin irritation.

An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.

An oral retinoid used in the treatment of keratotic genodermatosis, lichen planus, and psoriasis. Beneficial effects have also been claimed in the prophylaxis of epithelial neoplasia. The compound may be teratogenic.

Quick Search
Advertisement
 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Cytokine
Cytokines include chemokines, lymphokines, and monokines. Cells of the immune system communicate with one another by releasing and responding to chemical messengers called cytokines. These proteins are secreted by immune cells and act on other cells to...

Cytokine Tumour Necrosis Factor (TNF)
TNF is a compound that is classified as a cytokine which plays a central role in the cellular mechanisms of apoptosis or cell death. However, there are a number of different kinds of TNF, just under twenty, but the family of molecules have very similar a...

review and buy Ixekizumab (Taltz) market research data and corporate reports here

Channels Quicklinks